Hepatitis D and hepatocellular carcinoma

World Journal of Hepatology

Volumn 7, Issue 5, 2015, Pages 777-786

  Abbas, Zaigham ^a   Abbas, Minaam ^b   Abbas, Sarim ^c   Shazi, Lubna ^c  

^a SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Akber Centre   (Pakistan)

Author keywords

Cirrhosis; Epigenetic processes; Hepatitis d; Hepatocellular carcinoma; Necroinflammation; Oxidative stress

Indexed keywords

EID: 84929008307     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i5.777     Document Type: Article

References (110)

1. Dastgerdi ES, Herbers U, Tacke F. Molecular and clinical aspects of hepatitis D virus infections. World J Virol 2012; 1: 71-78 [PMID: 24175212 DOI: 10.5501/wjv.v1.i3.71]
2. Cunha C, Monjardino J, Cheng D, Krause S, Carmo-Fonseca M. Localization of hepatitis delta virus RNA in the nucleus of human cells. RNA 1998; 4: 680-693 [PMID: 9622127 DOI: 10.1017/ S135583829898013X]
3. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis 2012; 32: 228-236 [PMID: 22932971 DOI: 10.1055/s-0032-1323628]
4. Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, Vergani D, Williams R, Rizzetto M. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2: 945-947 [PMID: 6127458 DOI: 10.1016/ S0140-6736(82)90156-8]
5. Yurdaydi{dotless}n C, Idilman R, Bozkaya H, Bozdayi AM. Natural history and treatment of chronic delta hepatitis. J Viral Hepat 2010; 17: 749-756 [PMID: 20723036 DOI: 10.1111/j.1365-2893.2010.01353.x]
6. Heidrich B, Serrano BC, Idilman R, Kabaçam G, Bremer B, Raupach R, Önder FO, Deterding K, Zacher BJ, Taranta A, Bozkaya H, Zachou K, Tillmann HL, Bozdayi AM, Manns MP, Yurdaydi{dotless}n C, Wedemeyer H. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int 2012; 32: 1415-1425 [PMID: 22716112 DOI: 10.1111/j. 1478-3231.2012. 02831.x]
7. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
8. Romeo R. [Role of the hepatitis Delta virus on the pathogenesis of hepatic cirrhosis and hepatocellular carcinoma. Recent advances]. Recenti Prog Med 2010; 101: 52-56 [PMID: 20433000]
9. Wu JC, Chen TZ, Huang YS, Yen FS, Ting LT, Sheng WY, Tsay SH, Lee SD. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology 1995; 108: 796-802 [PMID: 7875481 DOI: 10.1016/0016-5085(95)90453-0]
10. Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis 2010; 28: 133-138 [PMID: 20460901 DOI: 10.1159/000282076]
11. Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol 2012; 18: 18-22 [PMID: 22249087 DOI: 10.4103/1319-3767.91731]
12. Abbas Z, Jafri W, Raza S. Hepatitis D: Scenario in the Asia-Pacific region. World J Gastroenterol 2010; 16: 554-562 [PMID: 20128022 DOI: 10.3748/wjg.v16.i5.554]
13. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, Krogsgaard K, Degos F, Carneiro de Moura M. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77-82 [PMID: 7806171]
14. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46: 420-426 [PMID: 10673308 DOI: 10.1136/gut.46.3.420]
15. Cross TJ, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, Vergani D, Harrison PM. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol 2008; 80: 277-282 [PMID: 18098143 DOI: 10.1002/jmv.21078]
16. Uzunalimoğlu O, Yurdaydin C, Cetinkaya H, Bozkaya H, Sahin T, Colakoğlu S, Tankurt E, Sarioğlu M, Ozenirler S, Akkiz H, Tözün N, Değertekin H, Okten A. Risk factors for hepatocellular carcinoma in Turkey. Dig Dis Sci 2001; 46: 1022-1028 [PMID: 11341644]
17. Değertekin H, Yalçin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol 2006; 17: 25-34 [PMID: 16830274]
18. Toukan AU, Abu-el-Rub OA, Abu-Laban SA, Tarawneh MS, Kamal MF, Hadler SC, Krawczynski K, Margolis HS, Maynard JE. The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan. Hepatology 1987; 7: 1340-1345 [PMID: 2824316 DOI: 10.1002/hep.1840070627]
19. Trichopoulos D, Day NE, Tzonou A, Hadziyannis S, Kaklamani E, Sparos L, Muñoz N, Hatzakis A. Delta agent and the etiology of hepatocellular carcinoma. Int J Cancer 1987; 39: 283-286 [PMID: 3028967 DOI: 10.1002/ijc.2910390303]
20. Gheorghe L, Iacob S, Simionov I, Vadan R, Gheorghe C, Iacob R, Parvulescu I, Constantinescu I. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol 2005; 14: 329-335 [PMID: 16400347]
21. Kurbanov F, Tanaka Y, Elkady A, Oyunsuren T, Mizokami M. Tracing hepatitis C and Delta viruses to estimate their contribution in HCC rates in Mongolia. J Viral Hepat 2007; 14: 667-674 [PMID: 17697020 DOI: 10.1111/j.1365-2893.2007.00864.x]
22. Tamura I, Kurimura O, Koda T, Ichimura H, Katayama S, Kurimura T, Inaba Y. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: a study from Kure, Japan. J Gastroenterol Hepatol 1993; 8: 433-436 [PMID: 8218990 DOI: 10.1111/j.1440-1746.1993.tb01543.x]
23. Huo TI, Wu JC, Lai CR, Lu CL, Sheng WY, Lee SD. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection. J Hepatol 1996; 25: 439-444 [PMID: 8912142 DOI: 10.1016/S0168-8278(96)80202-9]
24. Buti M, Homs M, Rodriguez-Frias F, Funalleras G, Jardí R, Sauleda S, Tabernero D, Schaper M, Esteban R. Clinical outcome of acute and chronic hepatitis delta over time: a long-term followup study. J Viral Hepat 2011; 18: 434-442 [PMID: 20546496 DOI: 10.1111/j.1365-2893.2010.01324.x]
25. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G, Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-1638 [PMID: 19208358 DOI: 10.1053/j.gastro.2009.01.052]
26. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst 2012; 104: 790-792 [PMID: 22423008 DOI: 10.1093/jnci/djs168]
27. Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One 2014; 9: e92062 [PMID: 24658127 DOI: 10.1371/journal. pone.0092062]
28. Oyunsuren T, Kurbanov F, Tanaka Y, Elkady A, Sanduijav R, Khajidsuren O, Dagvadorj B, Mizokami M. High frequency of hepatocellular carcinoma in Mongolia; association with mono-, or co-infection with hepatitis C, B, and delta viruses. J Med Virol 2006; 78: 1688-1695 [PMID: 17063518 DOI: 10.1002/jmv.20755]
29. Cenac A, Pedroso ML, Djibo A, Develoux M, Pichoud C, Lamothe F, Trepo C, Warter A. Hepatitis B, C, and D virus infections in patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma: a comparative study in Niger. Am J Trop Med Hyg 1995; 52: 293-296 [PMID: 7537942]
30. Oliveri F, Brunetto MR, Actis GC, Bonino F. Pathobiology of chronic hepatitis virus infection and hepatocellular carcinoma (HCC). Ital J Gastroenterol 1991; 23: 498-502 [PMID: 1661197]
31. Verme G, Brunetto MR, Oliveri F, Baldi M, Forzani B, Piantino P, Ponzetto A, Bonino F. Role of hepatitis delta virus infection in hepatocellular carcinoma. Dig Dis Sci 1991; 36: 1134-1136 [PMID: 1650690 DOI: 10.1007/BF01297460]
32. Smedile A, Rosina F, Saracco G, Chiaberge E, Lattore V, Fabiano A, Brunetto MR, Verme G, Rizzetto M, Bonino F. Hepatitis B virus replication modulates pathogenesis of hepatitis D virus in chronic hepatitis D. Hepatology 1991; 13: 413-416 [PMID: 1999312 DOI: 10.1002/hep.1840130305]
33. Huang YH, Wu JC, Chau GY, Tsay SH, King KL, Sheng WY, Lui WY, Lee SD. Detection of serum hepatitis B, C, and D viral nucleic acids and its implications in hepatocellular carcinoma patients. J Gastroenterol 1998; 33: 512-516 [PMID: 9719234 DOI: 10.1007/s005350050124]
34. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, Giustina G, Noventa F. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1994; 21: 656-666 [PMID: 7814813]
35. Kage M, Kosai K, Shimamatsu K, Nakashima O, Haramaki M, Yasunaga M, Iha H, Kojiro M, Govindarajan S. Incidence of hepatitis D virus infection in Japanese patients with hepatocellular carcinoma--immunohistochemical investigation of the delta antigen. Kurume Med J 1992; 39: 231-234 [PMID: 1339069 DOI: 10.2739/kurumemedj.39.231]
36. Tzonou A, Trichopoulos D, Kaklamani E, Zavitsanos X, Koumantaki Y, Hsieh CC. Epidemiologic assessment of interactions of hepatitis-C virus with seromarkers of hepatitis-B and-D viruses, cirrhosis and tobacco smoking in hepatocellular carcinoma. Int J Cancer 1991; 49: 377-380 [PMID: 1655659 DOI: 10.1002/ ijc.2910490311]
37. Tassopoulos NC, Theodoropoulos G, Sjogren MH, Engle R, Purcell RH. Serological markers of hepatitis B virus and hepatitis D virus infections in Greek adults with primary hepatocellular carcinoma. Infection 1989; 17: 17-19 [PMID: 2537800 DOI: 10.1007/BF01643493]
38. Chen DS, Lai MY, Sung JL. Delta agent infection in patients with chronic liver diseases and hepatocellular carcinoma--an infrequent finding in Taiwan. Hepatology 1984; 4: 502-503 [PMID: 6327488 DOI: 10.1002/hep.1840040324]
39. Govindarajan S, Hevia FJ, Peters RL. Prevalence of delta antigen/ antibody in B-viral-associated hepatocellular carcinoma. Cancer 1984; 53: 1692-1694 [PMID: 6321013]
40. Negro F, Papotti M, Taraglio S, Rubbia-Brandt L, Giostra E, Pacchioni D, Rizzetto M, Hadengue A. Relationship between hepatocyte proliferation and hepatitis delta virus replication in neoplastic and non-neoplastic liver tissues. J Viral Hepat 1997; 4: 93-98 [PMID: 9097264 DOI: 10.1111/j.1365-2893.1997.tb00210. x]
41. Wu JC, Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995; 346: 939-941 [PMID: 7564729 DOI: 10.1016/S0140-6736(95)915 58-3]
42. Wu JC. Functional and clinical significance of hepatitis D virus genotype II infection. Curr Top Microbiol Immunol 2006; 307: 173-186 [PMID: 16903226]
43. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, Lee PC, Lee SD, Wu JC. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006; 130: 1625-1635 [PMID: 16697726 DOI: 10.1053/j.gastro.2006.01.035]
44. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25: 3834-3847 [PMID: 16799625 DOI: 10.1038/ sj.onc.1209562]
45. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40 [PMID: 20051970 DOI: 10.1038/nrgastro.2009.205]
46. Williams V, Brichler S, Radjef N, Lebon P, Goffard A, Hober D, Fagard R, Kremsdorf D, Dény P, Gordien E. Hepatitis delta virus proteins repress hepatitis B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J Gen Virol 2009; 90: 2759-2767 [PMID: 19625466 DOI: 10.1099/vir.0.011239-0]
47. Pugnale P, Pazienza V, Guilloux K, Negro F. Hepatitis delta virus inhibits alpha interferon signaling. Hepatology 2009; 49: 398-406 [PMID: 19085955 DOI: 10.1002/hep.22654]
48. Ottobrelli A, Marzano A, Smedile A, Recchia S, Salizzoni M, Cornu C, Lamy ME, Otte JB, De Hemptinne B, Geubel A. Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology 1991; 101: 1649-1655 [PMID: 1955130]
49. Taylor JM. Hepatitis delta virus. Virology 2006; 344: 71-76 [PMID: 16364738 DOI: 10.1016/j.virol.2005.09.033]
50. Williams V, Brichler S, Khan E, Chami M, Dény P, Kremsdorf D, Gordien E. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress. J Viral Hepat 2012; 19: 744-753 [PMID: 22967106 DOI: 10.1111/j.1365-2893.2012.01597.x]
51. Waris G, Tardif KD, Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem Pharmacol 2002; 64: 1425-1430 [PMID: 12417255 DOI: 10.1016/ S0006-2952(02)01300-X]
52. Bureau C, Bernad J, Chaouche N, Orfila C, Béraud M, Gonindard C, Alric L, Vinel JP, Pipy B. Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem 2001; 276: 23077-23083 [PMID: 11304537 DOI: 10.1074/jbc.M100698200]
53. Chan SW, Egan PA. Hepatitis C virus envelope proteins regulate CHOP via induction of the unfolded protein response. FASEB J 2005; 19: 1510-1512 [PMID: 16006626 DOI: 10.1096/fj.04-3455fje]
54. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 9599-9604 [PMID: 11481452 DOI: 10.1073/ pnas.171311298]
55. Li S, Ye L, Yu X, Xu B, Li K, Zhu X, Liu H, Wu X, Kong L. Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-kappaB activation. Virology 2009; 391: 257-264 [PMID: 19628242 DOI: 10.1016/j.virol.2009.06.039]
56. Meyer M, Caselmann WH, Schlüter V, Schreck R, Hofschneider PH, Baeuerle PA. Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J 1992; 11: 2991-3001 [PMID: 1639069]
57. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375 [PMID: 11832451 DOI: 10.1053/gast.2002.30983]
58. Waris G, Huh KW, Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Mol Cell Biol 2001; 21: 7721-7730 [PMID: 11604508 DOI: 10.1128/MCB.21.22. 7721-7730.2001]
59. Benekli M, Baer MR, Baumann H, Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003; 101: 2940-2954 [PMID: 12480704 DOI: 10.1182/blood-2002-04-1204]
60. Feng DY, Zheng H, Jiang HY. [Effects of Stat3 phosphorylation and expression of c-fos and c-jun proteins on hepatocarcinogenesis]. Hunan Yike Daxue Xuebao 2001; 26: 17-19 [PMID: 12536605]
61. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002; 62: 6659-6666 [PMID: 12438264]
62. Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002; 21: 7001-7010 [PMID: 12370822 DOI: 10.1038/sj.onc.1205859]
63. de Mochel NS, Seronello S, Wang SH, Ito C, Zheng JX, Liang TJ, Lambeth JD, Choi J. Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology 2010; 52: 47-59 [PMID: 20578128 DOI: 10.1002/hep.23671]
64. Glenn JS, Watson JA, Havel CM, White JM. Identification of a prenylation site in delta virus large antigen. Science 1992; 256: 1331-1333 [PMID: 1598578 DOI: 10.1126/science.1598578]
65. Hwang SB, Lai MM. Isoprenylation mediates direct proteinprotein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen. J Virol 1993; 67: 7659-7662 [PMID: 8230486]
66. Choi SH, Jeong SH, Hwang SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. Gastroenterology 2007; 132: 343-357 [PMID: 17241884 DOI: 10.1053/j.gastro.2006.10.038]
67. Shih HH, Sheen IJ, Su CW, Peng WL, Lin LH, Wu JC. Hepatitis D virus isolates with low replication and epithelial-mesenchymal transition-inducing activity are associated with disease remission. J Virol 2012; 86: 9044-9054 [PMID: 22674995 DOI: 10.1128/ JVI.00130-12]
68. Park CY, Oh SH, Kang SM, Lim YS, Hwang SB. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling. Mol Cells 2009; 28: 49-55 [PMID: 19711042 DOI: 10.1007/s10059-009-0100-5]
69. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004; 6: 203-208 [PMID: 15380510 DOI: 10.1016/ j.ccr.2004.09.003]
70. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 Suppl: S81-S96 [PMID: 11983155 DOI: 10.1016/ S0092-8674(02)00703-1]
71. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260 [PMID: 9597130 DOI: 10.1146/ annurev.immunol.16.1.225]
72. Choi SH, Park KJ, Ahn BY, Jung G, Lai MM, Hwang SB. Hepatitis C virus nonstructural 5B protein regulates tumor necrosis factor alpha signaling through effects on cellular IkappaB kinase. Mol Cell Biol 2006; 26: 3048-3059 [PMID: 16581780 DOI: 10.1128/MCB.26.8.3048-3059.2006]
73. Park KJ, Choi SH, Lee SY, Hwang SB, Lai MM. Nonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor alpha-stimulated nuclear factor kappa B activation. J Biol Chem 2002; 277: 13122-13128 [PMID: 11821416]
74. Weil R, Sirma H, Giannini C, Kremsdorf D, Bessia C, Dargemont C, Bréchot C, Israël A. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol 1999; 19: 6345-6354 [PMID: 10454581]
75. Benegiamo G, Vinciguerra M, Guarnieri V, Niro GA, Andriulli A, Pazienza V. Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells. FEBS Lett 2013; 587: 1424-1428 [PMID: 23523924 DOI: 10.1016/j.febslet.2013.03.021]
76. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002; 416: 552-556 [PMID: 11932749 DOI: 10.1038/416552a]
77. Mota S, Mendes M, Freitas N, Penque D, Coelho AV, Cunha C. Proteome analysis of a human liver carcinoma cell line stably expressing hepatitis delta virus ribonucleoproteins. J Proteomics 2009; 72: 616-627 [PMID: 19136081 DOI: 10.1016/j.jprot.2008.12.003]
78. Kannan RP, Hensley LL, Evers LE, Lemon SM, McGivern DR. Hepatitis C virus infection causes cell cycle arrest at the level of initiation of mitosis. J Virol 2011; 85: 7989-8001 [PMID: 21680513 DOI: 10.1128/JVI.00280-11]
79. Liao FT, Lee YJ, Ko JL, Tsai CC, Tseng CJ, Sheu GT. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. J Gen Virol 2009; 90: 1124-1134 [PMID: 19264665 DOI: 10.1099/ vir.0.007211-0]
80. Huang WH, Mai RT, Lee YH. Transcription factor YY1 and its associated acetyltransferases CBP and p300 interact with hepatitis delta antigens and modulate hepatitis delta virus RNA replication. J Virol 2008; 82: 7313-7324 [PMID: 18480431 DOI: 10.1128/ JVI.02581-07]
81. Lee CZ, Sheu JC. Histone H1e interacts with small hepatitis delta antigen and affects hepatitis delta virus replication. Virology 2008; 375: 197-204 [PMID: 18314153 DOI: 10.1016/j.virol.2008.02.003]
82. Kang YK, Hong SW, Lee H, Kim WH. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol 2004; 35: 1340-1346 [PMID: 15668890 DOI: 10.1016/j.humpath.2004.07.021]
83. Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, Yang M, Guan XY. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006; 25: 1242-1250 [PMID: 16247463 DOI: 10.1038/sj.onc.1209141]
84. Redondo M, Villar E, Torres-Muñoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000; 157: 393-399 [PMID: 10934144 DOI: 10.1016/ S0002-9440(10)64552-X]
85. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I. Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol 2001; 5: 105-111 [PMID: 11690557 DOI: 10.1089/10915 360152559585]
86. Featherstone C, Jackson SP. Ku, a DNA repair protein with multiple cellular functions? Mutat Res 1999; 434: 3-15 [PMID: 10377944 DOI: 10.1016/S0921-8777(99)00006-3]
87. French LE, Wohlwend A, Sappino AP, Tschopp J, Schifferli JA. Human clusterin gene expression is confined to surviving cells during in vitro programmed cell death. J Clin Invest 1994; 93: 877-884 [PMID: 8113419 DOI: 10.1172/JCI117043]
88. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002; 34: 1430-1448 [PMID: 12200037]
89. Arozarena I, Matallanas D, Crespo P. Maintenance of CDC42 GDP-bound state by Rho-GDI inhibits MAP kinase activation by the exchange factor Ras-GRF. evidence for Ras-GRF function being inhibited by Cdc42-GDP but unaffected by CDC42-GTP. J Biol Chem 2001; 276: 21878-21884 [PMID: 11285260 DOI: 10.1074/jbc.M011383200]
90. Philipp T, Durazzo M, Trautwein C, Alex B, Straub P, Lamb JG, Johnson EF, Tukey RH, Manns MP. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994; 344: 578-581 [PMID: 7914961 DOI: 10.1016/S0140-6736(94)91966-6]
91. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674 [PMID: 21376230 DOI: 10.1016/j. cell.2011.02.013]
92. Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology 2009; 49: S56-S60 [PMID: 19399807 DOI: 10.1002/ hep.22962]
93. Kew MC, Miller RH, Chen HS, Tennant BC, Purcell RH. Mutant woodchuck hepatitis virus genomes from virions resemble rearranged hepadnaviral integrants in hepatocellular carcinoma. Proc Natl Acad Sci USA 1993; 90: 10211-10215 [PMID: 8234278 DOI: 10.1073/pnas.90.21.10211]
94. Renard CA, Fourel G, Bralet MP, Degott C, De La Coste A, Perret C, Tiollais P, Buendia MA. Hepatocellular carcinoma in WHV/ N-myc2 transgenic mice: oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles. Oncogene 2000; 19: 2678-2686 [PMID: 10851067]
95. Wang Z, Jin W, Jin H, Wang X. mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. Biomed Res Int 2014; 2014: 735672 [PMID: 24804240 DOI: 10.1155/2014/735672]
96. Xu X, Fan Z, Kang L, Han J, Jiang C, Zheng X, Zhu Z, Jiao H, Lin J, Jiang K, Ding L, Zhang H, Cheng L, Fu H, Song Y, Jiang Y, Liu J, Wang R, Du N, Ye Q. Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis. J Clin Invest 2013; 123: 630-645 [PMID: 23321675 DOI: 10.1172/JCI64265]
97. Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, Wu Z. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 2013; 25: 439-446 [PMID: 23124077 DOI: 10.1016/j.cellsig.2012.10.013]
98. Kimura O, Kondo Y, Shimosegawa T. PPAR Could Contribute to the Pathogenesis of Hepatocellular Carcinoma. PPAR Res 2012; 2012: 574180 [PMID: 23316217 DOI: 10.1155/2012/574180]
99. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J Clin Invest 2008; 118: 683-694 [PMID: 18188449 DOI: 10.1172/JCI33594]
100. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, Turner JR, Nakajima A, Borkan SC, Saubermann LJ. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005; 65: 2251-2259 [PMID: 15781638 DOI: 10.1158/0008-5472.CAN-04-3037]
101. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001; 61: 6213-6218 [PMID: 11507074]
102. Yu J, Shen B, Chu ES, Teoh N, Cheung KF, Wu CW, Wang S, Lam CN, Feng H, Zhao J, Cheng AS, To KF, Chan HL, Sung JJ. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 2010; 51: 2008-2019 [PMID: 20512989 DOI: 10.1002/hep.23550]
103. Shen B, Chu ES, Zhao G, Man K, Wu CW, Cheng JT, Li G, Nie Y, Lo CM, Teoh N, Farrell GC, Sung JJ, Yu J. PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer 2012; 106: 1486-1494 [PMID: 22472882 DOI: 10.1038/ bjc.2012.130]
104. Takayama O, Yamamoto H, Damdinsuren B, Sugita Y, Ngan CY, Xu X, Tsujino T, Takemasa I, Ikeda M, Sekimoto M, Matsuura N, Monden M. Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer 2006; 95: 889-895 [PMID: 16969348]
105. Leong PL, Andrews GA, Johnson DE, Dyer KF, Xi S, Mai JC, Robbins PD, Gadiparthi S, Burke NA, Watkins SF, Grandis JR. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003; 100: 4138-4143 [PMID: 12640143 DOI: 10.1073/ pnas.0534764100]
106. Nkongolo S, Ni Y, Lempp FA, Kaufman C, Lindner T, Esser-Nobis K, Lohmann V, Mier W, Mehrle S, Urban S. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol 2014; 60: 723-731 [PMID: 24295872 DOI: 10.1016/j.jhep.2013.11.022]
107. Freitas N, Salisse J, Cunha C, Toshkov I, Menne S, Gudima SO. Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. Hepatology 2012; 56: 76-85 [PMID: 22334419 DOI: 10.1002/hep.25663]
108. Naoumov NV. Cyclophilin inhibition as potential therapy for liver diseases. J Hepatol 2014; 61: 1166-1174 [PMID: 25048953 DOI: 10.1016/j.jhep.2014.07.008]
109. Chang MH. Hepatitis B virus and cancer prevention. Recent Results Cancer Res 2011; 188: 75-84 [PMID: 21253790 DOI: 10.1007/978-3-642-10858-7_6]
110. Abbas Z, Khan MA, Salih M, Jafri W. Interferon alpha for chronic hepatitis D. Cochrane Database Syst Rev 2011; (12): CD006002 [PMID: 22161394 DOI: 10.1002/14651858.CD006002.pub2]